Literature DB >> 1486568

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

G Rege-Cambrin1, P Scaravaglio, F Carozzi, S Giordano, C Ponzetto, P M Comoglio, G Saglio.   

Abstract

MKN 45 is a poorly differentiated gastric carcinoma cell line from which the subclone GTL 16 was obtained. Both lines carry an amplification unit derived from chromosome 7 sequences and containing an activated c-met oncogene. Karyotypic analysis showed that GTL 16 derived from a subclone of MKN 45 after endoreduplication. Several clonal abnormalities are evident in both lines; some are frequently observed in gastrointestinal tumors (loss of 17p and monosomy 18). Other consistent anomalies include 6q-, t(8;10) and t(5;8), and inv(16). A marker chromosome (M1), which was previously shown to contain the c-met amplification unit, is constantly duplicated in all GTL 16 metaphases; in contrast, most unidentified markers are retained in only a single copy in GTL 16 cells. These data are in agreement with the hypothesis that the c-met oncogene activation in these gastric cancer cell lines might be related to a gene dosage effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486568     DOI: 10.1016/0165-4608(92)90350-h

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  23 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Authors:  Yohei Funakoshi; Toru Mukohara; Hideo Tomioka; Roudy Chiminch Ekyalongo; Yu Kataoka; Yumiko Inui; Yuriko Kawamori; Masanori Toyoda; Naomi Kiyota; Yutaka Fujiwara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2013-04-09       Impact factor: 3.850

3.  Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.

Authors:  Jeffrey R Infante; Terence Rugg; Michael Gordon; Isabelle Rooney; Lee Rosen; Karin Zeh; Raymond Liu; Howard A Burris; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2012-05-01       Impact factor: 3.850

4.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

5.  Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments.

Authors:  Gregory J Kimmel; Mark Dane; Laura M Heiser; Philipp M Altrock; Noemi Andor
Journal:  Cancer Res       Date:  2020-09-16       Impact factor: 12.701

Review 6.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

7.  EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Authors:  Gianluca Sala; Ilario Giovanni Rapposelli; Reza Ghasemi; Enza Piccolo; Sara Traini; Emily Capone; Cosmo Rossi; Angela Pelliccia; Annalisa Di Risio; Maurizia D'Egidio; Nicola Tinari; Raffaella Muraro; Stefano Iacobelli
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  Chromosome spreading techniques for primary gastrointestinal tumors.

Authors:  K Sasai; R Tanaka; M Kawamura; K Honjo; N Matsunaga; T Nakada; K Homma; H Fujimura
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

9.  Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

Authors:  Simona Corso; Elena Ghiso; Virna Cepero; J Rafael Sierra; Cristina Migliore; Andrea Bertotti; Livio Trusolino; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-05-26       Impact factor: 27.401

10.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Authors:  Gromoslaw A Smolen; Raffaella Sordella; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Heidi Archibald; Woo J Kim; Ross A Okimoto; Daphne W Bell; Dennis C Sgroi; James G Christensen; Jeffrey Settleman; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.